Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Amicus Therapeutics' Cash from Investing Activities fell 10379.03% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.3 million, marking a year-over-year decrease of 136254.55%. This contributed to the annual value of -$560000.0 for FY2024, which is 10057.11% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Cash from Investing Activities of -$1.3 million as of Q3 2025, which was down 10379.03% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Cash from Investing Activities ranged from a high of $86.6 million in Q1 2021 and a low of -$68.1 million during Q4 2021
  • In the last 5 years, Amicus Therapeutics' Cash from Investing Activities had a median value of $25.7 million in 2021 and averaged $12.0 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Cash from Investing Activities soared by 12244.05% in 2021, and later plummeted by 53599.58% in 2025.
  • Amicus Therapeutics' Cash from Investing Activities (Quarter) stood at -$68.1 million in 2021, then grew by 2.03% to -$66.7 million in 2022, then surged by 64.08% to -$24.0 million in 2023, then grew by 14.88% to -$20.4 million in 2024, then surged by 93.63% to -$1.3 million in 2025.
  • Its Cash from Investing Activities stands at -$1.3 million for Q3 2025, versus -$5.8 million for Q2 2025 and -$32.9 million for Q1 2025.